Merck’s drug prolongs survival in advanced stomach, esophageal cancers in trial
Merck announced that its experimental cancer drug, sacituzumab tirumotecan, extends the survival of patients with advanced stomach and esophageal cancers compared to standard treatments.
Full story
Read the full story at Arab News ↗
Continue reading this story on Arab News, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.